Bulk Pharmaceutical API Sources for VEMURAFENIB

Bulk Pharmaceutical API Sources for VEMURAFENIB

Vendor	Vendor Homepage	Vendor Sku	API Url
MolPort		MolPort-009-200-481
ABBLIS Chemicals		AB1009703
Amadis Chemical		A25476
AKos Consulting & Solutions		AKOS007930804
Adooq BioScience		PLX4032 - Vemurafenib
Inhibitor 2		Vemurafenib
AbMole Bioscience		1761

Bulk API Sources for Vemurafenib

Last updated: February 20, 2026

Vemurafenib (brand name Zelboraf) is a BRAF kinase inhibitor approved for the treatment of BRAF V600 mutation-positive melanoma. Securing reliable bulk sources of its active pharmaceutical ingredient (API) is critical for manufacturing, research, and supply chain continuity.

Who Are the Major API Manufacturers for Vemurafenib?

The API manufacturing landscape for Vemurafenib is limited, with a handful of Chinese and Indian suppliers dominating the market.

Supplier	Location	Production Status	Certifications	Estimated Capacity (kg/year)	Comments
Zhejiang Huahai Pharmaceutical	China	Produces Vemurafenib API for global markets	cGMP, ISO 9001, ISO 14001	20-50	Primary bulk supplier for generic API
Hetero Labs Ltd.	India	Supplies Vemurafenib API for regional and export markets	cGMP, ISO certifications	10-30	Offers competitive pricing
Sun Pharmaceutical Industries	India	Limited publicly available data on Vemurafenib API production	cGMP, ISO 9001	Unknown	Likely involved as a contract manufacturer or API source
Meryer (Shanghai) Chemical Technology	China	Offers chemical intermediates; possible API contracted production	cGMP (by request)	Unknown	Focuses on intermediates, may partner for API supply

Supply Chains and Regulatory Status

• Chinese suppliers: Zhejiang Huahai's API production complies with WHO and U.S. FDA standards, with exports to North America and Europe. Their API has been involved in supply chains for generics and authorized combinations.

• Indian suppliers: Hetero Labs and Sun Pharma are known for their broad portfolio and manufacturing scale. Their APIs are approved in India and often exported under various regulatory frameworks.

Quality and Regulatory Considerations

Supply quality varies widely across suppliers. International regulators prefer API manufacturers with cGMP certification and recent audit records.

• Approval status: APIs from Zhejiang Huahai and Hetero have valid approvals or clearances for global markets.
• Analytical specifications: Usually include assay, impurities, residual solvents, and stability data aligned with ICH Q7 guidelines.
• Traceability: Suppliers providing batch documentation, stability data, and validation reports aid in regulatory approvals.

Challenges to API Sourcing

• Regulatory restrictions: Some Chinese suppliers have faced scrutiny related to compliance, affecting importability to U.S. and EU markets.
• Capacity constraints: As demand for BRAF inhibitors grows, API suppliers may face capacity limitations, leading to longer lead times.
• Pricing volatility: Market fluctuations and raw material availability influence API costs.

Contract Manufacturing and Outsourcing Trends

• Major pharmaceutical companies may contract third-party manufacturers for Vemurafenib API, reducing dependence on single-source suppliers.
• Contract manufacturing organizations (CMOs) in India and China are active in producing APIs under cGMP standards, often offering flexible capacity.

Summary of Key API Sources

Source	Location	Certification	Capacity Estimate	Notes
Zhejiang Huahai	China	cGMP	20-50 kg/year	Main bulk supplier; global reach
Hetero Labs	India	cGMP	10-30 kg/year	Competitive pricing, regional supply
Sun Pharma	India	Internal compliance	Unknown	Likely concedes as a contract manufacturer

Key Considerations for Procurement

• Verify supplier certifications and recent audit reports.
• Confirm regulatory approvals for intended markets.
• Evaluate capacity constraints and lead time.
• Negotiate pricing based on production volume and certification status.
• Conduct quality assessments, including analytical data review and site audits if necessary.

Key Takeaways

• Vemurafenib API is sourced primarily from manufacturing facilities in China and India.
• Leading suppliers include Zhejiang Huahai (China) and Hetero Labs (India).
• Regulatory compliance, quality assurance, and capacity are critical factors impacting sourcing decisions.
• API supply chains are influenced by geopolitical, regulatory, and market dynamics.
• Contract manufacturing relationships play a significant role in ensuring supply security.

FAQs

1. What are the main regulatory considerations when sourcing Vemurafenib API?
Suppliers must have cGMP certification and approval in target markets. Documentation, validation data, and past audit records are critical.

2. Can Vemurafenib API be sourced commercially from only Chinese and Indian suppliers?
Primarily, yes. These countries dominate the API production market for Vemurafenib, though other regions may engage in contract manufacturing.

3. How do capacity limitations impact API procurement?
Limited capacity can result in longer lead times and potential shortages, especially as demand for BRAF inhibitors rises.

4. Is there a risk of regulatory restrictions on Chinese API imports?
Yes. Geopolitical factors and compliance issues can affect importability; due diligence is required.

5. What is the typical lead time for Vemurafenib API supply?
Lead times range from 6 to 12 weeks, depending on supplier capacity, order size, and regulatory clearance.

---

References

[1] U.S. Food and Drug Administration (FDA). (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] World Health Organization (WHO). (2021). WHO Global Benchmarking Tool—Manufacturing Capabilities.
[3] Indian Pharmaceutical Alliance. (2021). Indian API Industry Report.
[4] China Food and Drug Administration. (2022). API Manufacturing and Export Regulations.
[5] Market Watch. (2023). Global API Market Trends and Supply Chain Analysis.